Growth hormone and growth factors

This class groups together peptides and related compounds commonly discussed in the context of growth hormone (GH) signaling, GH secretagogues, and downstream growth-factor biology. Examples include GHRH analogs (e.g., sermorelin), ghrelin receptor agonists / GHRPs, GH analogs, and IGF-related research peptides.

In many cases, public discussion moves faster than formal clinical evidence. Regulatory status, product quality, and anti-doping status may vary widely across molecules.

Mechanistic themes vary by molecule, but often include one or more of the following:

• Stimulating endogenous GH release via hypothalamic/pituitary signaling (GHRH analogs) or via ghrelin receptor pathways (GHRPs)

• Delivering GH activity directly (GH analogs) rather than stimulating secretion

• Targeting downstream growth pathways (IGF and growth-factor signaling) in experimental models

These pathways are physiologically potent and can affect multiple organ systems. Interpreting claims requires attention to endpoints, dosing, and the difference between short-term biomarkers and long-term outcomes.

Some members of this broad category have established medical uses in regulated settings (for example, prescription GH in specific deficiency contexts), while many other peptides in the “GH / growth factors” space are primarily encountered as research materials.

In sport, a large portion of this category is restricted or prohibited — growth hormone, its releasing factors, and GH secretagogues appear on the WADA Prohibited List. If anti-doping rules apply, those rules generally dominate the risk picture.

Common discussion themes include dose-related side effects, metabolic changes, injection-site issues, and the risk of inappropriate use outside regulated indications. For research peptides, additional uncertainty is introduced by manufacturing variability and the absence of robust pharmacovigilance.

Entries in this catalog may include GH secretagogues, GH analogs, and growth-factor peptides. Catalog listings are structural references only and do not comment on appropriateness of any product, source, or protocol.

Evidence in this space often ranges from physiology and biomarker work to preclinical studies and (for some regulated medicines) larger human datasets. When evaluating claims, it helps to ask whether the cited evidence addresses:

• Clinical outcomes vs short-term biomarkers
• Population studied (deficiency vs enhancement contexts)
• Duration (short-term changes vs long-term risk/benefit)

How do GH secretagogues differ from GH analogs?

Secretagogues (GHRH analogs like sermorelin, and ghrelin-pathway agents like the GHRPs) prompt the pituitary to release its own growth hormone, so output stays partly under the body's feedback control. GH analogs deliver growth hormone activity directly, bypassing that regulation. The distinction matters for pulsatility, feedback effects, and how each type is studied and regulated.

What kinds of evidence exist across this class?

It ranges widely. Prescription growth hormone has decades of clinical data in its approved deficiency indications, and a few secretagogues have completed formal development for specific uses — tesamorelin, for example, is an approved medicine labeled for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (DailyMed label). Many other compounds in this space — IGF-related fragments and most research-grade secretagogues — rest mainly on early-stage or preclinical work, so evidence must be assessed molecule by molecule.

Why does anti-doping status dominate discussions of this class?

Growth hormone, its releasing factors, and secretagogues are broadly prohibited in sport, and detection methods continue to improve. For athletes subject to testing, that prohibition applies regardless of a compound's evidence base or regulatory status, which is why anti-doping rules generally dominate the risk picture for this category.